Skip to main content

Human Aggrecan G1-IGD-G2 Domains Antibody

R&D Systems, part of Bio-Techne | Catalog # MAB1220

R&D Systems, part of Bio-Techne
Catalog #
Availability
Size / Price
Qty
Loading...
MAB1220
MAB1220-SP

Key Product Details

Species Reactivity

Validated:

Human

Cited:

Human

Applications

Validated:

Immunohistochemistry, Immunoprecipitation, Western Blot

Cited:

ELISA Development, Immunohistochemistry, Immunohistochemistry-Paraffin

Label

Unconjugated

Antibody Source

Monoclonal Mouse IgG2B Clone # 179509

Product Specifications

Immunogen

Mouse myeloma cell line NS0-derived recombinant human Aggrecan
Val20-Gly675
Accession # NP_037359

Specificity

Detects human Aggrecan G1-IGD-G2 Domains in Western blots and direct ELISAs.

Clonality

Monoclonal

Host

Mouse

Isotype

IgG2B

Scientific Data Images for Human Aggrecan G1-IGD-G2 Domains Antibody

Detection of Mouse Human Aggrecan G1-IGD-G2 Domains Antibody by Immunocytochemistry/ Immunofluorescence

Detection of Mouse Human Aggrecan G1-IGD-G2 Domains Antibody by Immunocytochemistry/ Immunofluorescence

Olanzapine (Oz) and haloperidol (Hp) modify the density of excitatory and inhibitory synapses to excitatory and inhibitory neurons. (a) The principle of the synapse quantification method is based on the detection of presynaptic and postsynaptic markers. (b) The overlap between presynaptic and postsynaptic fluorescence allows to identify the structurally complete synapses. Neurotransmitter transporter proteins are labeled in red at the presynapse, scaffolding protein is marked green at the postsynapse. (c) Glutamatergic and GABAergic synapses are detected with reference to aggrecan expression in 21 days in vitro (21 DIV) neuronal cultures. The representative 66.5 × 66.5 µm single plane confocal micrographs exemplify the staining patterns of excitatory (colocalization of PSD95 and VGlut1) and inhibitory (colocalization of gephyrin and VGAT) synapses in proximity to inhibitory (aggrecan-positive) and excitatory (aggrecan-negative) neuron somata (See explanation in the text). High-resolution scans were obtained from the regions proximal to neuronal somata. Scale bar, 30 µm. (d) The percent of increase/decrease in synapse density upon treatment with antipsychotics is shown as median (square center), and the inter quartile range (25–75% IQR whiskers). Each data point reflects the quantification of minimum 35 images (66.5 × 66.5 µm area, containing a single cell body of a 21 DIV neuron, exemplified in (c), N = 5. The asterisks indicate significant differences with the corresponding control, based on the Kruskal-Wallis ANOVA test (*p < 0.05; ***p < 0.001). Image collected and cropped by CiteAb from the following publication (https://pubmed.ncbi.nlm.nih.gov/28912551), licensed under a CC-BY license. Not internally tested by R&D Systems.

Aggrecan in Human Cartilage.

Aggrecan was detected in immersion fixed paraffin-embedded sections of human cartilage using Mouse Anti-Human Aggrecan G1-IGD-G2 Domains Monoclonal Antibody (Catalog # MAB1220) at 5 µg/mL for 1 hour at room temperature followed by incubation with the Anti-Mouse IgG VisUCyte™ HRP Polymer Antibody (VC001). Before incubation with the primary antibody, tissue was subjected to heat-induced epitope retrieval using Antigen Retrieval Reagent-Basic (CTS013). Tissue was stained using DAB (brown) and counterstained with hematoxylin (blue). Specific staining was localized to chondrocytes. Staining was performed using our protocol for IHC Staining with VisUCyte HRP Polymer Detection Reagents.

Applications for Human Aggrecan G1-IGD-G2 Domains Antibody

Application
Recommended Usage

Immunohistochemistry

5-25 µg/mL
Sample: Immersion fixed paraffin-embedded sections of human cartilage

Immunoprecipitation

25 µg/mL
Sample: Conditioned cell culture medium spiked with Recombinant Human Aggrecan G1-IGD-G2 Domains (Catalog # 1220-PG), see our available Western blot detection antibodies

Western Blot

1 µg/mL
Sample: Recombinant Human Aggrecan G1-IGD-G2 Domains (Catalog # 1220-PG)
under non-reducing conditions only
Please Note: Optimal dilutions of this antibody should be experimentally determined.

Formulation, Preparation, and Storage

Purification

Protein A or G purified from hybridoma culture supernatant

Reconstitution

Reconstitute at 0.5 mg/mL in sterile PBS. For liquid material, refer to CoA for concentration.

Reconstitution Buffer Available:
Size / Price
Qty
Loading...

Formulation

Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied either lyophilized or as a 0.2 µm filtered solution in PBS.

Shipping

Lyophilized product is shipped at ambient temperature. Liquid small pack size (-SP) is shipped with polar packs. Upon receipt, store immediately at the temperature recommended below.

Stability & Storage

Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 6 months, -20 to -70 °C under sterile conditions after reconstitution.

Background: Aggrecan

Aggrecan, also known as aggrecan 1, chondroitin sulfate proteoglycan, and large aggregating proteoglycan, is encoded by the AGC1 gene with gene aliases of SEDK; CSPG1; MSK16; CSPGCP (1). As the key component of the cartilage extracellular matrix, aggrecan hydrates the collagen network and provides cartilage with its properties of compressibility and elasticity. Maintenance of aggrecan content is therefore critical to the function of the tissue and aggrecan degradation is an important factor in the erosion of articular cartilage in arthritic diseases (2). The deduced amino acid sequence of human aggrecan core protein consists of 2415 residues and predicts a signal peptide and domains of G1, IGD, G2, KS, CS-1, CS-2 and G3 (3). Two globular domains, G1 and G2, comprise the N-terminus of the proteoglycan and also contain link domains. The third globular domain, G3, corresponds to the C-terminus. The keratan sulfate (KS) and the chondroitin sulfate (CS) attachment domains are between G2 and G3. With KS and CS attached to the 250 kDa core protein, aggrecan monomers exist as a 1,000 to 2,000 kDa molecule. In addition, aggrecan monomers interact with hyaluronan through their G1 domain, resulting in larger aggregates containing 10 to 100 aggrecan monomers on a hyaluronan backbone (2). Aggrecan can be cleaved by MMPs and ADAMTSs at the Asn360-Phe361 and Glu392-Ala393 bond in the IGD (residues are numbered based on Accession # NP_037359), respectively (2). Inhibition of ADATMS4 and ADAMTS5 cleavage prevents aggrecan degradation in osteoarthritic cartilage, while mice with aggrecan resistant to MMP cleavage do not accumulate aggrean and develop normally (2, 4).

References

  1. Doege. K.J. et al. (1991) J. Biol. Chem. 266:894.
  2. Malfait, A.-M. et al. (2002) J. Biol. Chem. 277:22201.
  3. Caterson, B. et al. (2000) Matrix Biol. 19:333.
  4. Little, C.B. et al. (2005) Mol. Cel. Biol. 25:3388.

Alternate Names

ACAN, AGC1, CSPG1, CSPGCP, MSK16, SEDK

Entrez Gene IDs

176 (Human)

Gene Symbol

ACAN

UniProt

Additional Aggrecan Products

Product Documents for Human Aggrecan G1-IGD-G2 Domains Antibody

Certificate of Analysis

To download a Certificate of Analysis, please enter a lot number in the search box below.

Note: Certificate of Analysis not available for kit components.

Product Specific Notices for Human Aggrecan G1-IGD-G2 Domains Antibody

For research use only

Loading...
Loading...
Loading...
Loading...